생물제제 안전성 시험 시장 : 오퍼링 유형별, 시험 유형별, 모달리티 유형별, 기술 유형별, 지역별 - 동향과 예측(-2035년)

Biologics Safety Testing Market by Type of Offering, Type of Testing, Type of Modality, Type of Technology and Geographical Regions - Trends and Forecast, Till 2035

US $ 4,799 ￦ 7,244,000

PDF (Single User License)

PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 6,999 ￦ 10,564,000

PDF (One-Location Site License)

PDF 보고서를 동일 사업장의 특정 사업 부문에 속한 모든 분들이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 10,599 ￦ 15,999,000

PDF (Department License)

PDF 보고서를 부서 단위로 12명까지 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 17,999 ￦ 27,169,000

PDF (Enterprise License)

PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

한글목차

생물제제 안전성 시험 시장 : 개요

세계의 생물제제 안전성 시험 시장 규모는 현재 53억 달러에서 2035년까지 94억 달러로 성장하며, 예측 기간(-2035년)의 CAGR은 6.6%로 추정되고 있습니다.

생물제제 안전성 시험 시장 : 성장 및 동향

생물제제는 단백질, 탄수화물, 핵산 또는 이들 성분의 혼합물 등 다양한 생체 분자로 구성된 복잡한 치료제입니다. 생물제제는 일반적으로 생물에 의해 생산되며 빛, 온도, pH, 산소 농도 등 환경 영향에 매우 민감합니다.

생물제제는 생물학적 기원과 구조적 복잡성으로 인해 면역원성(원치 않는 면역반응), 오염, 로트 간 변동성 등 다양한 안전 위험을 초래할 수 있습니다. 이러한 문제를 해결하기 위해 치료용 분자가 유해한 불순물을 포함하지 않고, 확실히 효과적이며, 인간에게 적용해도 안전하다는 것을 확인하기 위해 안전성 시험이 필수적입니다. 이러한 문제를 해결하기 위해 생물제제 안전성 시험은 임상 적용 또는 시판 전에 생물제제의 안전성, 순도, 유효성 및 일관성을 검증하기 위한 엄격한 절차입니다. 만성질환의 유병률 증가와 맞춤형 의료의 도입으로 첨단 치료법에 대한 수요가 급증함에 따라 생물제제 안전성 시험 시장은 예측 기간 중 견고한 성장을 보일 것으로 예측됩니다.

성장 요인 - 시장 확대의 전략적 원동력

생물제제 안전성 시험 시장을 촉진하는 주요 요인으로는 생물제제 및 첨단 치료법에 대한 수요 증가를 들 수 있습니다. 이로 인해 이들 제품에 대한 철저한 안전성 테스트가 필요하게 되었습니다. 또한 차세대 염기서열 분석 등 첨단 기술을 통해 생물제제내 불순물, 오염물질, 안전성 위험을 신속하게 검출 및 식별할 수 있게 되었습니다. 또한 규제 당국은 생물제제의 철저한 평가에 있으며, 첨단 안전성 시험 프로토콜의 중요성을 더욱 인식하고 있습니다. 그 결과, 오염물질, 면역원성, 바이러스 안전성 및 생물제제 제조시 일관성에 대한 광범위한 테스트가 필요한 종합적인 가이드라인을 수립했습니다.

시장 과제 - 발전을 가로막는 심각한 장애물

생물의약품 안전성 시험 시장은 지속적으로 성장하고 있지만, 그 보급을 방해하는 문제들이 여전히 존재하고 있습니다. 첨단 장비, 시약 및 내부 역량과 관련된 높은 비용은 중소기업의 부담으로 작용하여 시장 진출을 제한하고 외부 위탁에 대한 의존도를 높이고 있습니다. 또한 복잡하고 지역별로 상이한 규제는 기준의 차이로 인해 컴플라이언스 지연, 승인 과정의 장기화, 개발 비용 증가로 이어지고 있습니다. 생물제제의 복잡성이 증가함에 따라 시험에 대한 수요가 증가하고 있지만, 지속가능성에 대한 우려는 비용 문제를 충분히 해결하지 못한 채 운영상의 문제를 야기하고 있습니다.

생물제제 안전성 시험 시장 - 주요 연구 결과

이 보고서는 생물제제 안전성 시험 시장의 현황을 상세하게 분석하고 업계내 잠재적인 성장 기회를 파악합니다. 주요 조사 결과는 다음과 같습니다.

• 생물제제 안전성 시험 서비스 제공 기업의 60%가 내독소 시험 서비스를 제공합니다. 흥미롭게도, 서비스 제공 기업의 약 55%가 백신의 안전성 프로파일 평가에 다양한 기술을 채택하고 있습니다.

• 경쟁 우위를 확보하고 진화하는 업계 요구사항에 대응하기 위해 이해관계자들은 각 회사의 서비스 포트폴리오를 개선하고 기존 역량을 적극적으로 강화하고 있습니다.
• 전 세계에서 약 40여 개의 기업이 생물제제 안전성 시험 솔루션을 제공합니다. 특히 생물제제 안전성 시험 프로바이더의 80% 이상이 조사 목적의 솔루션을 제공합니다.
• 현재 생물제제 안전성 시험 솔루션 제공 기업의 75% 이상이 중합효소연쇄반응(PCR) 기술을 채택하고 있으며, 50%의 솔루션 제공 기업이 세포치료제 안전성 시험 솔루션 제공을 표명하고 있습니다.
• 업계 이해관계자들은 환자의 안전을 보장하고 엄격한 규제 요건을 충족하기 위해 다양한 최종사용자가 이용할 수 있는 생물제제 안전성 시험 솔루션의 혁신과 개발을 적극적으로 추진하고 있습니다.
• 이 분야에서 체결된 대부분의 거래는 인수합병으로, 시장 범위를 확장하고 다양한 지역에서 전문적인 바이오안전성 테스트 솔루션의 가용성을 확보하는 데에 전략적 초점을 맞추었습니다.
• 지난 수년간 생물제제 안전성 시험 솔루션 제공 업체는 다양한 자금 조달 라운드를 통해 52억 달러 이상을 조달했습니다. 이 중 90% 이상이 북미에 기반을 둔 기업별로 조달되고 있습니다.

• 지난 2년간 생물학적제제 안전성 시험 관련 특허의 약 40%가 부여되었으며, 대부분의 특허(89%)가 업계 진출기업별로 출원되고 있습니다.
• 생물제제 안전성 시험 시장은 2035년까지 안정적인 성장이 예상되며, 가까운 미래에 소모품이 시장 점유율의 대부분(60% 이상)을 차지할 것으로 예측됩니다.
• 현재 시장 점유율의 대부분은 항체 하위 부문이 차지하고 있습니다. 이는 암, 자가면역질환, 감염질환에 대한 표적치료에 중요한 역할을 하는 모노클로널 항체의 보급에 힘입은 바 큽니다.
• 미국의 생물제제 안전성 시험 시장은 주로 복잡한 생물제제 증가와 생물제제 안전성 시험을 필요로 하는 만성질환의 유병률 증가에 의해 주도되고 있습니다.
• 생물제제 안전성 시험 시장은 2035년까지 약 7.1%의 연평균 복합 성장률(CAGR)을 보일 것으로 예측됩니다. 시장 점유율의 대부분(약 60%)은 생물학적제제 안전성 시험용 소모품이 차지할 것으로 예측됩니다.

• 복잡한 생물제제의 개발이 급증하고 기술 발전과 함께 생물제제 안전성 시험 산업은 미래 성장을 위해 좋은 위치에 있습니다.

생물제제 안전성 시험 시장

시장 규모 및 기회 분석은 다음 매개 변수를 기반으로 세분화됩니다.

제공 제품 유형별

• 소모품
• 장비
• 서비스

시험 유형별

• 바이러스 안전성 시험
• 마이코플라즈마 시험
• 무균 시험
• 내독소 검사
• 바이오버든 테스트
• 기타 시험

모달리티 유형별

• 항체
• 백신
• 세포치료
• 유전자 치료
• 바이오시밀러
• 기존 바이러스 기반 치료법
• 단백질
• 기타 치료법

기술 유형별

• 중합효소 연쇄반응
• 기존 기술
• 크로마토그래피 및 전기영동 기술
• 차세대 시퀀싱
• 기타 기술

최종사용자별

• 제약-바이오 기업
• 수탁연구기관/수탁개발 제조기관
• 학술-연구기관

지역별

• 북미
• 미국
• 캐나다
• 유럽
• 독일
• 영국
• 프랑스
• 이탈리아
• 스페인
• 기타 유럽
• 아시아태평양
• 중국
• 일본
• 인도
• 한국
• 기타 아시아태평양
• 중동 및 북아프리카
• 사우디아라비아
• 이집트
• 기타 중동·북아프리카
• 라틴아메리카
• 브라질
• 아르헨티나
• 기타 라틴아메리카

생물제제 안전성 시험 시장 : 주요 부문

소모품이 생물제제 안전성 시험 시장에서 가장 큰 점유율을 차지하고 있습니다.

생물제제 안전성 시험 시장 분석에 따르면 소모품 하위 부문이 시장을 독점하고 있으며(60%), 이는 생물제제 안전성 시험에 필수적인 소모품에 대한 수요 증가에 기인합니다. 또한 장비는 더 높은 CAGR로 성장할 가능성이 높으며, 예측 기간 중 상당한 성장 잠재력을 보여주고 있습니다. 이는 장비의 도입으로 전체 워크플로우의 효율성과 인적 오류를 줄일 수 있기 때문입니다.

바이러스 안전성 테스트가 향후 가장 큰 점유율을 차지할 것입니다.

생물제제 안전성 시험 시장 예측에서 바이러스 안전성 시험 하위 부문이 가장 큰 점유율(약 30%)을 차지할 것으로 예측됩니다. 이는 만성질환의 발생률 증가와 새로운 생물제제 치료의 수용 확대가 그 배경입니다. 마이코플라즈마 검사는 예측 기간 중 상당한 성장 기회를 나타내는 높은 CAGR을 보일 것으로 예측됩니다. 이러한 성장은 주로 생물제제 제조시 마이코플라즈마 오염에 대한 철저한 검사를 요구하는 엄격한 규제 요건에 기인합니다.

항체 부문이 올해 생물제제 안전성 시험 시장에서 가장 큰 점유율을 차지할 것으로 예측됩니다.

시장 분석에 따르면 항체 하위 부문은 생물제제 안전성 시험 시장 점유율의 약 35%를 차지합니다. 이러한 선도적 지위는 뛰어난 특이성, 적응성, 입증된 효율성에 기인합니다. 또한 종양학, 자가면역질환, 감염질환 등 다양한 치료용도를 가지고 있으며, 생물제제 안전성 시험에 대한 수요가 증가하고 있습니다. 백신은 예측 기간 중 높은 CAGR을 보일 것으로 예상되며, 예측 기간 중 상당한 성장 잠재력을 보여줄 것으로 예측됩니다. 이러한 증가는 백신 승인 건수 증가와 다양한 적응증에 대한 지속적인 연구와 관련이 있습니다.

중합효소연쇄반응(PCR)이 올해 생물제제 안전성 시험 시장에서 가장 큰 점유율을 차지할 것으로 보입니다.

시장 세분화에서 전체 시장은 중합효소 연쇄반응(PCR), 전통적 방법, 크로마토그래피 및 전기영동법, 차세대 시퀀싱, 기타 기술 등 다양한 기술 유형으로 분류됩니다. 중합효소연쇄반응(PCR) 하위 부문은 올해 생물학적제제 안전성 시험 시장에서 약 35%라는 큰 점유율을 차지하고 있습니다. 이러한 우위는 최근 폴리머레이즈 연쇄반응 기술의 발전으로 인한 것입니다. 이 기술은 정확도 향상, 절대 정량화, 다중 표적의 동시 검출 능력을 제공하여 검사 효율성과 신뢰성을 높입니다. 또한 고처리량 스크리닝을 위한 PCR 기술의 자동화가 용이하여 여러 오염물질을 동시에 검출할 수 있습니다. 이러한 자동화는 생물학적제제 안전성 시험 연구소의 업무 효율성을 향상시키고 검사 비용을 절감할 수 있습니다.

북미가 가장 큰 점유율을 확보하며 시장을 독점합니다.

생물제제 안전성 시험 시장 분석에 따르면 첨단 분자 검사 기술의 도입 확대에 따라 제약 및 생명공학 기업은 올해 생물제제 안전성 시험 시장의 대부분(약 50%의 점유율)을 차지할 것으로 예측됩니다. 이는 연구개발(R&D)의 강력한 역량, 막대한 자금 투자, 그리고 증가하는 세계 보건 문제에 대응하기 위해 설계된 혁신적인 생물제제의 탄탄한 파이프라인에 기인합니다. 제약 및 생명공학 기업은 예측 기간 중 7.8%의 높은 CAGR을 달성하여 높은 성장 잠재력을 보일 것으로 예측됩니다.

생물의약품 안전성 시험 시장 대표 진출기업

• BioMerieux
• Charles River Laboratories
• Clean Cells
• Eurofins
• Genezen
• SGS
• Solvias
• Texcell
• Vimta Labs
• Wickham Micro

생물제제 안전성 시험 시장 : 조사 범위

• 시장 규모 및 기회 분석 : 이 보고서는 생물학적 안전성 시험 시장에 대해(A) 제공 형태,(B) 시험 유형,(C) 양식 유형,(D) 기술 유형,(E) 지역적 지역과 같은 주요 시장 부문에 초점을 맞춘 상세한 분석을 제공합니다.
• 생물제제 안전성 시험 서비스 프로바이더 시장 현황: 생물제제 안전성 시험 서비스 프로바이더 시장 전반에 대한 종합적인 시장 현황과 함께(A)설립연도,(B)기업 규모,(C)본사 소재지,(D)인증/허가,(E)제공 서비스 유형,(F)시험 방법 유형,(G)지원 시료 유형,(H)기술 유형 H) 기술 유형,(I) 최종사용자 등 관련 파라미터에 대한 정보를 상세하게 제공합니다.
• 생물제제 안전성 시험 서비스 프로바이더의 경쟁력 분석 :(A) 공급업체의 강점,(B) 서비스 강점,(C) 포트폴리오의 다양성을 바탕으로 생물제제 안전성 시험 서비스 프로바이더에 대한 인사이트 분석.
• 생물제제 안전성 시험 솔루션 제공 기업 시장 현황: 생물제제 안전성 시험 서비스 제공 기업 시장 전체에 대한 상세한 평가와 함께(A) 설립 연도,(B) 기업 규모,(C) 본사 소재지,(D) 제공 형태,(E) 시험 유형,(F) 수행 방법 유형,(G) 분석 대상 시료 유형,(H) 기술 유형,(I) 애플리케이션 유형,(J) 최종사용자 정보 포함 기술 유형,(I) 응용 분야,(J) 최종사용자에 대한 정보를 포함합니다.
• 생물제제 안전성 시험 솔루션 제공 기업의 경쟁력 분석 :(A) 공급 능력,(B) 서비스 능력,(C) 포트폴리오의 다양성을 바탕으로 생물제제 안전성 시험 솔루션 제공 기업에 대한 인사이트 분석.
• 기업 개요: 북미, 유럽, 아시아태평양의 생물제제 안전성 시험 분야에 종사하는 주요 기업의 상세한 프로파일을(A) 설립연도,(B) 본사 소재지,(C) 제품 포트폴리오,(D) 최근 동향,(E) 향후 전망에 기반하여 제공합니다.
• 제휴/협력 관계: 이해관계자간 체결된 제휴/협력 관계를(A) 제휴 연도,(B) 제휴 형태,(C) 파트너 유형,(F) 가장 활발한 진출 기업 등 여러 관련 파라미터를 기반으로 분석합니다.
• 자금조달 및 투자 분석 : 생물학적제제 안전성 시험 시장에 참여하는 이해관계자별 자금조달 및 투자 실태를(A) 자금조달 연도,(B) 투자금액,(C) 자금조달 형태,(D) 지역별 분포,(E) 가장 활발하게 진출한 기업 등 관련 파라미터를 기준으로 상세하게 분석합니다.
• 특허 분석 : 생물제제 안전성 시험과 관련된 각종 특허에 대해(A) 공개 연도,(B) 특허 유형,(C) 출원 연도,(D) 특허 관할권,(E) 주요 개인 권리자 등 여러 관련 파라미터를 기반으로 상세한 분석을 수행합니다.
• 시장 영향 분석 : 생물제제 안전성 시험 시장의 성장에 영향을 미칠 수 있는 요인에 대한 상세한 분석입니다. 또한(A) 주요 촉진요인,(B) 잠재적 제약 요인,(C) 새로운 기회,(D) 기존 과제 파악 및 시장 분석도 포함됩니다.

목차

제1장 보고서의 개요

제2장 조사 방법

제3장 시장 역학

제4장 거시경제 지표

제5장 개요

제6장 서론

제7장 시장 구도 : 생물제제 안전성 시험 서비스 프로바이더

제8장 기업 경쟁력 분석 : 생물제제 안전성 시험 서비스 프로바이더

제9장 시장 구도 : 생물제제 안전성 시험 솔루션 프로바이더

제10장 기업 경쟁력 분석 : 생물제제 안전성 시험 솔루션 프로바이더

제11장 기업 개요 생물제제 안전성 시험 프로바이더

제12장 파트너십과 협업

제13장 자금조달과 투자

제14장 특허 분석

제15장 시장 영향 분석

제16장 세계의 생물제제 안전성 시험 시장

제17장 생물제제 안전성 시험 시장(오퍼링 유형별)

제18장 생물제제 안전성 시험 시장(시험 유형별)

제19장 생물제제 안전성 시험 시장(모달리티별)

제20장 생물제제 안전성 시험 시장(기술별)

제21장 생물제제 안전성 시험 시장(최종사용자별)

제22장 생물제제 안전성 시험 시장(지역별)

제23장 시장 기회 분석 : 북미

제24장 시장 기회 분석 : 유럽

제25장 시장 기회 분석 : 아시아태평양

제26장 시장 기회 분석 : 중동 및 북아프리카

제27장 시장 기회 분석 : 라틴아메리카

제28장 Porter's Five Forces 분석

제29장 결론

제30장 이그제큐티브 인사이트

제31장 부록 I : 표 데이터

제32장 부록 II : 기업 및 조직 리스트

KSA

영문 목차

영문목차

Biologics Safety Testing Market: Overview

As per Roots Analysis, the global biologics safety testing market is estimated to grow from USD 5.3 billion in the current year to USD 9.4 billion by 2035, at a CAGR of 6.6% during the forecast period, till 2035.

Biologics Safety Testing Market: Growth and Trends

Biologics are intricate therapeutic agents made up of different biomolecules, including proteins, carbohydrates, nucleic acids, or a mix of these components. Biologics are typically produced by living organisms and are extremely responsive to environmental influences, such as light, temperature, pH, and oxygen concentrations.

Biologics can present various safety risks due to their biological origin and structural complexity, including immunogenicity (undesired immune reactions), contamination, and variability between batches. To tackle these issues, safety testing is essential for confirming that these therapeutic molecules are devoid of hazardous impurities, reliably effective, and safe for human application. To tackle this, biologics safety testing is a rigorous procedure aimed at verifying biologic safety, purity, potency, and consistency prior to clinical application or market launch. Driven by surging demand for advanced therapies amid rising chronic disease prevalence and personalized medicine adoption, the biologics safety testing market is poised for robust growth during the forecast period.

Growth Drivers: Strategic Enablers of Market Expansion

Key factors driving the biologics safety testing market include the increasing demand for biologics and advanced therapies, which creates a need for thorough safety testing of these products. Moreover, cutting-edge technologies like next generation sequencing allow for quicker detection and identification of impurities, contaminants, and safety risks in biologics. Furthermore, regulatory agencies are becoming more aware of the importance of advanced safety testing protocols for the thorough assessment of biologic products. As a result, they are establishing comprehensive guidelines that necessitate extensive testing for contaminants, immunogenicity, viral safety, and consistency in the manufacturing of biologics.

Market Challenges: Critical Barriers Impeding Progress

Challenges continue to exist in the biologics safety testing market, even with its ongoing growth, which obstructs quicker adoption. The high costs associated with advanced equipment, reagents, and internal capabilities strain small to mid-sized companies, limiting their market reach and increasing their dependence on outsourcing. Additionally, intricate and region-specific regulations lead to compliance delays, longer approval processes, and increased development costs due to varying standards. The increasing complexity of biologics raises the demands for testing, while sustainability concerns introduce operational challenges without adequately addressing the cost issues.

Biologics Safety Testing Market: Key Insights

The report delves into the current state of the biologics safety testing market and identifies potential growth opportunities within industry. Some key findings from the report include:

• 60% of the biologics safety testing service providers offer endotoxin testing services; interestingly, close to 55% of the service providers are employing various technologies to evaluate safety profile of vaccines.

• In pursuit of gaining a competitive edge and to meet the evolving industry requirements, stakeholders are actively enhancing their existing capabilities by improving their respective service portfolios.
• Close to 40 companies are engaged in offering biologics safety testing solutions across the globe; notably, over 80% of the biologics safety testing providers offer solutions for research purpose.
• Presently, more than 75% of the biologics safety testing solution providers use polymerase chain reaction technique; 50% of the solution providers claim to offer safety testing solutions for cell therapies.
• Industry stakeholders are actively innovating and developing biologics safety testing solutions that can be utilized by various end-users to ensure patient safety and meet stringent regulatory requirements.
• Majority of the deals inked in this domain were acquisitions, indicating a strategic focus on expanding market reach and ensuring availability of specialized biosafety testing solutions across diverse geographic regions.
• In the past few years, over USD 5.2 billion has been raised by biologics safety testing solution providers across various funding rounds; of these, >90% of the total amount was raised by players based in North America.

• Close to 40% of the patents have been granted related to biologics safety testing in the last two years; further, most of the patents have been filed by industry players (89%).
• The biologics safety testing market is anticipated to grow at a steady rate, till 2035; consumables are expected to capture the majority share (more than 60%) of the market in foreseeable future.
• Currently, majority of the market share is captured by antibodies subsegment owing to the widespread use of monoclonal antibodies, which play a vital role in targeted therapies for cancer, autoimmune, and infectious diseases.
• The US biologics safety testing market is primarily driven by the rising number of complex biologics and prevalence of chronic disorders necessitating the need for biologics safety testing.
• The biologics safety testing market is likely to grow at an annualized rate (CAGR) of ~7.1%, till 2035; majority of the market share (~60%) is expected to be captured by biologics safety testing consumables.

• Given the surge in development of complex biologics, combined with technological advancements, the biologics safety testing industry is well-positioned for future growth.

Biologics Safety Testing Market

The market sizing and opportunity analysis has been segmented across the following parameters:

By Type of Offering

• Consumables
• Instruments
• Services

By Type of Testing

• Virus Safety Testing
• Mycoplasma Testing
• Sterility Testing
• Endotoxin Testing
• Bioburden Testing
• Other Testing

By Type of Modality

• Antibodies
• Vaccines
• Cell Therapies
• Gene Therapies
• Biosimilars
• Traditional viral-based Therapies
• Proteins
• Other Modalities

By Type of Technology

• Polymerase Chain Reaction
• Traditional Techniques
• Chromatographic and Electrophoretic Techniques
• Next-Generation Sequencing
• Other Technologies

By End-user

• Pharmaceutical and Biotechnology Companies
• Contract Research Organizations / Contract Development and Manufacturing Organizations
• Academic and Research Institutes

By Geographical Regions

• North America
• US
• Canada
• Europe
• Germany
• UK
• France
• Italy
• Spain
• Rest of Europe
• Asia-Pacific
• China
• Japan
• India
• South Korea
• Rest of Asia-Pacific
• Middle East and North Africa
• Saudi Arabia
• Egypt
• Rest of Middle East and North Africa
• Latin America
• Brazil
• Argentina
• Rest of Latin America

Biologics Safety Testing Market: Key Segments

Consumables Account for the Largest Biologics Safety Testing Market Share

According to the biologics safety testing market analysis, the consumables sub-segment dominates the market (60%), driven by the increased demand for consumables, essential for biologics safety testing. Further, instruments are likely to grow at a higher CAGR, showcasing substantial growth potential during the forecast period. This is because the adoption of instruments can streamline the overall workflow and reduce human error.

Virus Safety Testing Hold the Highest Share in the Future

The forecast for the biologics safety testing market indicates that the virus safety testing sub-segment holds the largest share (approximately 30%), fueled by the increasing incidence of chronic illnesses and the growing acceptance of novel biologic treatments. Mycoplasma testing is expected to experience a higher compound annual growth rate (CAGR), demonstrating significant growth opportunities during the forecast period. This growth is largely attributed to stringent regulatory requirements that necessitate thorough testing for mycoplasma contamination in the production of biologics.

Antibodies Segment Holds the Highest Biologics Safety Testing Market Share in the Current Year

As per market analysis, the antibodies sub-segment represents approximately 35% of the biologics safety testing market share. This leading position is largely attributed to their remarkable specificity, adaptability, and proven efficiency. Furthermore, they possess a wide array of therapeutic uses, including in the fields of oncology, autoimmune disorders, and infectious diseases, which creates a demand for biological safety testing. Vaccines are expected to experience a higher compound annual growth rate (CAGR), indicating significant growth potential throughout the forecast period. This increase can be linked to the rising number of vaccine approvals and their ongoing investigation for various target indications.

Polymerase Chain Reaction Holds the Highest Biologics Safesty Testing Market Share in the Current Year

The overall market is segmented into various technology types, including polymerase chain reaction, traditional methods, chromatographic and electrophoretic methods, next-generation sequencing, and other technologies. The polymerase chain reaction sub-segment holds a significant share of the biologics safety testing market (~35%) this year. This dominance is attributed to recent advancements in polymerase chain reaction technology that provide greater accuracy, absolute quantification, and the capability to detect multiple targets simultaneously, thus improving testing efficiency and reliability. Additionally, the ease of automating PCR technologies for high-throughput screening allows for the simultaneous detection of several contaminants. Such automation enhances operational efficiency and lowers testing costs for biological safety testing laboratories.

North America Dominates the Market by Securing Highest Share

As per the analysis of the biologics safety testing market, the growing implementation of advanced molecular testing technologies is expected to enable pharmaceutical and biotechnology firms to capture a significant portion of the biologics safety testing market (approximately 50% share) in the current year. This is attributed to their strong capabilities in research and development (R&D), considerable financial investments, and robust pipelines of innovative biologics designed to meet the increasing global health challenges. Pharmaceutical and biotechnology firms are predicted to experience a higher compound annual growth rate (CAGR) of 7.8%, indicating considerable growth potential throughout the forecast period.

Primary Research Overview

Discussions with multiple stakeholders in this domain influenced the opinions and insights presented in this study. The market report includes transcripts of the following other third-party discussions:

• Business Development Officer, Mid-sized Organization, Austria
• Business Development Director, Mid-sized Organization, Poland

In addition, the market report includes transcripts of the following other third-party discussions:

• R&D Scientist and Product Manager, Very Large Organization, Germany
• Scientific Expert, Very Large Organization, United States

Example Players in Biologics Safety Testing Market

• BioMerieux
• Charles River Laboratories
• Clean Cells
• Eurofins
• Genezen
• SGS
• Solvias
• Texcell
• Vimta Labs
• Wickham Micro

Biologics Safety Testing Market: Research Coverage

• Market Sizing and Opportunity Analysis: The report features an in-depth analysis of the biologics safety testing market, focusing on key market segments, including [A] type of offering [B] type of testing, [C] type of modality, [D] type of technology, and [E] geographical regions.
• Biologics Safety Testing Service Providers Market Landscape: A detailed assessment of the overall biologics safety testing service providers market landscape, along with information on several relevant parameters, such as [A] year of establishment, [B] company size, [C] location of headquarters, [D] certification / accreditation, [E] type of service offered [F] type of modality, [G] type of sample supported, [H type of technology, and [I] end user.
• Competitiveness Analysis of Biologics Safety Testing Service Providers: An insightful analysis of biologics safety testing service providers based on the [A] supplier strength and [B] service strength and [C] portfolio diversity.
• Biologics Safety Testing Solution Providers Market Landscape: A detailed assessment of the overall biologics safety testing service providers market landscape, along with information on several relevant parameters, such as [A] year of establishment, [B] company size, [C] location of headquarters, [D] type of offering, [E] type of testing [F] type of modality, [G] type of sample analyzed, [H type of technology, [I] application area and [J] end user.
• Competitiveness Analysis of Biologics Safety Testing Solution Providers: An insightful analysis of biologics safety testing solution providers based on the [A] supplier strength and [B] service strength and [C] portfolio diversity.
• Company Profiles: In-depth profiles of leading players engaged in biologics safety testing domain in North America, Europe and Asia-Pacific based on [A] year of establishment, [B] location of headquarters, [C] product portfolio, [D] recent developments and [E] an informed future outlook.
• Partnerships and Collaborations: An analysis of partnerships and collaborations inked between stakeholders, based on several relevant parameters, such as [A] year of partnership, [B] type of partnership, [C] type of partner, and [F] most active players.
• Funding and Investment Analysis: A detailed analysis of the funding and investments raised by stakeholders engaged in the biologics safety testing market, based on several relevant parameters, such as [A] year of funding, [B] amount invested, [C] type of funding, [D] regional distribution, [E] and most active players.
• Patent Analysis: an in-depth analysis of various patents that have been filed / granted for biologics safety testing based on several relevant parameters, such as [A] publication year, [B] type of patent, [C] application year, [D] patent jurisdiction, [E] and leading individual assignees.
• Market Impact Analysis: An in-depth analysis of the factors that can impact the growth of the biologics safety testing market. It also features identification and market analysis of [A] key drivers, [B] potential restraints, [C] emerging opportunities, and [D] existing challenges.

Key Questions Answered in this Report

• Which are the leading companies in biologics safety testing market?
• Which region dominates the biologics safety testing market?
• What are the key trends observed in the biologics safety testing market?
• What factors are likely to influence the evolution of this market?
• What are the primary challenges faced by biologics safety testing service providers?
• What is the current and future market size?
• What is the CAGR of this market?
• How is the current and future market opportunity likely to be distributed across key market segments?

Reasons to Buy this Report

• The report provides a comprehensive market analysis, offering detailed revenue projections of the overall market and its specific sub-segments. This information is valuable to both established market leaders and emerging entrants.
• The report offers stakeholders a comprehensive overview of the market, including key drivers, barriers, opportunities, and challenges. This information empowers stakeholders to stay abreast of market trends and make data-driven decisions to capitalize on growth prospects.
• The report can aid businesses in identifying future opportunities in any sector. It also helps in understanding if those opportunities are worth pursuing.
• The report helps in identifying customer demand by understanding the needs, preferences, and behavior of the target audience in order to tailor products or services effectively.
• The report equips new entrants with requisite information regarding a particular market to help them build successful business strategies.
• The report allows for more effective communication with the audience and in building strong business relations.

Additional Benefits

• Complementary PPT Insights Pack
• Complimentary Excel Data Packs for all Analytical Modules in the Report
• 15% Free Content Customization
• Detailed Report Walkthrough Session with Research Team
• Free Updated report if the report is 6-12 months old or older

TABLE OF CONTENTS

1 REPORT OVERVIEW

• 1.1. Context
• 1.2. Project Objectives

2 RESEARCH METHODOLOGY

• 2.1. Chapter Overview
• 2.2. Research Assumptions
  • 2.2.1. Market Landscape and Market Trends
  • 2.2.2. Market Forecast and Opportunity Analysis
  • 2.2.3. Comparative Analysis
• 2.3. Database Building
  • 2.3.1. Data Collection
  • 2.3.2. Data Validation
  • 2.3.3. Data Analysis
• 2.4. Project Methodology
  • 2.4.1. Secondary Research
    • 2.4.1.1. Annual Reports
    • 2.4.1.2. Academic Research Papers
    • 2.4.1.3. Company Websites
    • 2.4.1.4. Investor Presentations
    • 2.4.1.5. Regulatory Filings
    • 2.4.1.6. White Papers
    • 2.4.1.7. Industry Publications
    • 2.4.1.8. Conferences and Seminars
    • 2.4.1.9. Government Portals
    • 2.4.1.10. Media and Press Releases
    • 2.4.1.11. Newsletters
    • 2.4.1.12. Industry Databases
    • 2.4.1.13. Roots Proprietary Databases
    • 2.4.1.14. Paid Databases and Sources
    • 2.4.1.15. Social Media Portals
    • 2.4.1.16. Other Secondary Sources
  • 2.4.2. Primary Research
    • 2.4.2.1. Types of Primary Research
      • 2.4.2.1.1. Qualitative Research
      • 2.4.2.1.2. Quantitative Research
      • 2.4.2.1.3. Hybrid Approach
    • 2.4.2.2. Advantages of Primary Research
    • 2.4.2.3. Techniques for Primary Research
      • 2.4.2.3.1. Interviews
      • 2.4.2.3.2. Surveys
      • 2.4.2.3.3. Focus Groups
      • 2.4.2.3.4. Observational Research
      • 2.4.2.3.5. Social Media Interactions
    • 2.4.2.4. Key Opinion Leaders Considered in Primary Research
      • 2.4.2.4.1. Company Executives (CXOs)
      • 2.4.2.4.2. Board of Directors
      • 2.4.2.4.3. Company Presidents and Vice Presidents
      • 2.4.2.4.4. Research and Development Heads
      • 2.4.2.4.5. Technical Experts
      • 2.4.2.4.6. Subject Matter Experts
      • 2.4.2.4.7. Scientists
      • 2.4.2.4.8. Doctors and Other Healthcare Providers
    • 2.4.2.5. Ethics and Integrity
      • 2.4.2.5.1. Research Ethics
      • 2.4.2.5.2. Data Integrity
  • 2.4.3. Analytical Tools and Databases
• 2.5. Robust Quality Control

3 MARKET DYNAMICS

• 3.1. Chapter Overview
• 3.2. Forecast Methodology
  • 3.2.1. Top-down Approach
  • 3.2.2. Bottom-up Approach
  • 3.2.3. Hybrid Approach
• 3.3. Market Assessment Framework
  • 3.3.1. Total Addressable Market (TAM)
  • 3.3.2. Serviceable Addressable Market (SAM)
  • 3.3.3. Serviceable Obtainable Market (SOM)
  • 3.3.4. Currently Acquired Market (CAM)
• 3.4. Forecasting Tools and Techniques
  • 3.4.1. Qualitative Forecasting
  • 3.4.2. Correlation
  • 3.4.3. Regression
  • 3.4.4. Extrapolation
  • 3.4.5. Convergence
  • 3.4.6. Sensitivity Analysis
  • 3.4.7. Scenario Planning
  • 3.4.8. Data Visualization
  • 3.4.9. Time Series Analysis
  • 3.4.10. Forecast Error Analysis
• 3.5. Key Considerations
  • 3.5.1. Demographics
  • 3.5.2. Government Regulations
  • 3.5.3. Reimbursement Scenarios
  • 3.5.4. Market Access
  • 3.5.5. Supply Chain
  • 3.5.6. Industry Consolidation
  • 3.5.7. Pandemic / Unforeseen Disruptions Impact
• 3.6. Limitations

4 MACRO-ECONOMIC INDICATORS

• 4.1. Chapter Overview
• 4.2. Market Dynamics
  • 4.2.1. Time Period
    • 4.2.1.1. Historical Trends
    • 4.2.1.2. Current and Forecasted Estimates
  • 4.2.2. Currency Coverage
    • 4.2.2.1. Major Currencies Affecting the Market
    • 4.2.2.2. Factors Affecting Currency Fluctuations
    • 4.2.2.3. Impact of Currency Fluctuations on the Industry
  • 4.2.3. Foreign Currency Exchange Rate
    • 4.2.3.1. Impact of Foreign Exchange Rate Volatility on the Market
    • 4.2.3.2. Strategies for Mitigating Foreign Exchange Risk
  • 4.2.4. Recession
    • 4.2.4.1. Assessment of Current Economic Conditions and Potential Impact on the Market
    • 4.2.4.2. Historical Analysis of Past Recessions and Lessons Learnt
  • 4.2.5. Inflation
    • 4.2.5.1. Measurement and Analysis of Inflationary Pressures in the Economy
    • 4.2.5.2. Potential Impact of Inflation on the Market Evolution
  • 4.2.6. Interest Rates
    • 4.2.6.1. Interest Rates and Their Impact on the Market
    • 4.2.6.2. Strategies for Managing Interest Rate Risk
  • 4.2.7. Commodity Flow Analysis
    • 4.2.7.1. Type of Commodity
    • 4.2.7.2. Origins and Destinations
    • 4.2.7.3. Values and Weights
    • 4.2.7.4. Modes of Transportation
  • 4.2.8. Global Trade Dynamics
    • 4.2.8.1. Import Scenario
    • 4.2.8.2. Export Scenario
    • 4.2.8.3. Trade Policies
    • 4.2.8.4. Strategies for Mitigating the Risks Associated with Trade Barriers
    • 4.2.8.5. Impact of Trade Barriers on the Market
  • 4.2.9. War Impact Analysis
    • 4.2.9.1. Russian-Ukraine War
    • 4.2.9.2. Israel-Hamas War
  • 4.2.10. COVID Impact / Related Factors
    • 4.2.10.1. Global Economic Impact
    • 4.2.10.2. Industry-specific Impact
    • 4.2.10.3. Government Response and Stimulus Measures
    • 4.2.10.4. Future Outlook and Adaptation Strategies
  • 4.2.11. Other Indicators
    • 4.2.11.1. Fiscal Policy
    • 4.2.11.2. Consumer Spending
    • 4.2.11.3. Gross Domestic Product (GDP)
    • 4.2.11.4. Employment
    • 4.2.11.5. Taxes
    • 4.2.11.6. Stock Market Performance
    • 4.2.11.7. Cross-Border Dynamics
• 4.3. Conclusion

5 EXECUTIVE SUMMARY

• 5.1. Executive Summary: Market Landscape
• 5.2. Executive Summary: Market Trends
• 5.3. Executive Summary: Market Forecast and Opportunity Analysis

6 INTRODUCTION

• 6.1. Overview of Biologics Safety Testing
• 6.2. Key Biosafety Tests
• 6.3. Challenges in the Biologics Safety Domain
• 6.4. Recent Developments in the Biologics Safety Testing Domain
• 6.5. Future Perspectives

7 MARKET LANDSCAPE: BIOLOGICS SAFETY TESTING SERVICE PROVIDERS

• 7.1. Methodology and Key Parameters
• 7.2. Biologics Safety Testing Service Providers: Overall Market Landscape
  • 7.2.1. Analysis by Year of Establishment
  • 7.2.2. Analysis by Company Size
  • 7.2.3. Analysis by Location of Headquarters
  • 7.2.4. Analysis by Certification / Accreditation
  • 7.2.5. Analysis by Type of Service Offered
  • 7.2.6. Analysis by Type of Modality
  • 7.2.7. Analysis by Type of Sample Supported
  • 7.2.8. Analysis by Type of Technology
  • 7.2.9. Analysis by End-user

8 COMPANY COMPETITIVENESS ANALYSIS: BIOLOGICS SAFETY TESTING SERVICE PROVIDERS

• 8.1. Methodology and Key Parameters
• 8.2. Scoring Criteria
• 8.3. Peer Groups
• 8.4. Biologics Safety Testing Service Providers: Company Competitiveness Analysis
  • 8.4.1. Biologics Safety Testing Service Providers Offering Services for Vaccines
  • 8.4.2. Biologics Safety Testing Service Providers Offering Services for Cell Therapies
  • 8.4.3. Biologics Safety Testing Service Providers Offering Services for Gene Therapies
  • 8.4.4. Biologics Safety Testing Service Providers Offering Services for Antibodies
  • 8.4.5. Biologics Safety Testing Service Providers Offering Services for Proteins
  • 8.4.6. Biologics Safety Testing Service Providers Offering Services for Other Modalities

9 MARKET LANDSCAPE: BIOLOGICS SAFETY TESTING SOLUTION PROVIDERS

• 9.1. Methodology and Key Parameters
• 9.2. Biologics Safety Testing Solution Providers: Overall Market Landscape
  • 9.2.1. Analysis by Year of Establishment
  • 9.2.2. Analysis by Company Size
  • 9.2.3. Analysis by Location of Headquarters
  • 9.2.4. Analysis by Type of Offering
  • 9.2.5. Analysis by Type of Testing
  • 9.2.6. Analysis by Type of Modality
  • 9.2.7. Analysis by Type of Sample Analyzed
  • 9.2.8. Analysis by Type of Technology
  • 9.2.9. Analysis by Application Area
  • 9.2.10. Analysis by End-user

10 COMPANY COMPETITIVENESS ANALYSIS: BIOLOGICS SAFETY TESTING SOLUTION PROVIDERS

• 10.1. Methodology and Key Parameters
• 10.2. Scoring Criteria
• 10.3. Peer Groups
  • 10.3.1. Overview of Peer Groups
• 10.4. Biologics Safety Testing Solution Providers: Company Competitiveness Analysis
  • 10.4.1. Biologics Safety Testing Solution Providers Headquartered in North America
  • 10.4.2. Biologics Safety Testing Solution Providers Headquartered in Europe
  • 10.4.3. Biologics Safety Testing Solution Providers Headquartered in Asia-Pacific and Rest of the world

11 COMPANY PROFILES: BIOLOGICS SAFETY TESTING PROVIDERS

• 11.1. Chapter Overview
• 11.2. BioMerieux
  • 11.2.1. Company Overview
  • 11.2.2. Service Portfolio
  • 11.2.3. Financial Information
  • 11.2.4. Recent Developments and Future Outlook
• 11.3. Charles River Laboratories
• 11.4. Clean Cells
• 11.5. Eurofins
• 11.6. Genezen
• 11.7. SGS
• 11.8. Solvias
• 11.9. Texcell
• 11.10. Vimta Labs
• 11.11. Wickham Micro

12 PARTNERSHIPS AND COLLABORATIONS

• 12.1. Partnership Models
• 12.2. Biologics Safety Testing: Partnerships and Collaborations
  • 12.2.1. Analysis by Year of Partnership
  • 12.2.2. Analysis by Type of Partnership
  • 12.2.3. Analysis by Year and Type of Partnership
  • 12.2.4. Analysis by Type of Biologic
  • 12.2.5. Analysis by Type of Testing
  • 12.2.6. Analysis by Type of Partner
  • 12.2.7. Most Active Players: Analysis by Number of Partnerships
  • 12.2.8. Analysis by Geography
    • 12.2.8.1. Local and International Deals
    • 12.2.8.2. Intracontinental and Intercontinental Deals

13 FUNDING AND INVESTMENTS

• 13.1. Funding Models
• 13.2. Funding Lifecycle Analysis
• 13.3. Investment Case: Risk and Return
• 13.4. Biologics Safety Testing: Funding and Investments
  • 13.4.1. Analysis of Instances by Year of Funding
  • 13.4.2. Analysis of Instances by Type of Funding
  • 13.4.3. Analysis of Instances by Year and Type of Funding
  • 13.4.4. Analysis of Amount by Year of Funding
  • 13.4.5. Analysis of Amount by Type of Funding
  • 13.4.6. Analysis by Geography
  • 13.4.7. Key Industry Players: Analysis by Number of Funding Instances
  • 13.4.8. Most Active Players: Analysis by Amount Invested
  • 13.4.9. Most Active Investors: Analysis by Number of Funding Instances
  • 13.4.10. Summary of Investments

14 PATENT ANALYSIS

• 14.1. Methodology and Key Parameters
• 14.2. Biologics Safety Testing: Patent Analysis
  • 14.2.1. Analysis by Publication Year
  • 14.2.2. Analysis by Type of Patent
  • 14.2.3. Analysis by Patent Application Year
  • 14.2.4. Analysis by Patent Age
  • 14.2.5. Analysis by Type of Applicant
  • 14.2.6. Analysis by Patent Jurisdiction
  • 14.2.7. Analysis by CPC Symbols
  • 14.2.8. Leading Industry Players: Analysis by Number of Patents
  • 14.2.9. Leading Non-Industry Players: Analysis by Number of Patents
  • 14.2.10. Leading Individual Assignees: Analysis by Number of Patents
• 14.3. Biologics Safety Testing: Patent Benchmarking
• 14.4. Biologics Safety Testing: Patent Valuation

15 MARKET IMPACT ANALYSIS

• 15.1. Market Drivers
• 15.2. Market Restraints
• 15.3. Market Opportunities
• 15.4. Market Challenges

16 GLOBAL BIOLOGICS SAFETY TESTING MARKET

• 16.1. Key Assumptions and Methodology
• 16.2. Global Biologics Safety Testing Market, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
  • 16.2.1. Scenario Analysis
    • 16.2.1.1. Conservative Scenario
    • 16.2.1.2. Optimistic Scenario
• 16.3. Key Market Segments

17 BIOLOGICS SAFETY TESTING MARKET, BY TYPE OF OFFERING

• 17.1. Key Assumptions and Methodology
• 17.2. Biologics Safety Testing Market: Distribution by Type of Offering
  • 17.2.1. Biologics Safety Testing Market for Consumables, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
  • 17.2.2. Biologics Safety Testing Market for Instruments, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
  • 17.2.3. Biologics Safety Testing Market for Services, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)

18 BIOLOGICS SAFETY TESTING MARKET, BY TYPE OF TESTING

• 18.1. Key Assumptions and Methodology
• 18.2. Biologics Safety Testing Market: Distribution by Type of Testing
  • 18.2.1. Biologics Safety Testing Market for Virus Safety Testing, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
  • 18.2.2. Biologics Safety Testing Market for Mycoplasma Testing, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
  • 18.2.3. Biologics Safety Testing Market for Sterility Testing, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
  • 18.2.4. Biologics Safety Testing Market for Endotoxin Testing, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
  • 18.2.5. Biologics Safety Testing Market for Bioburden Testing, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
  • 18.2.6. Biologics Safety Testing Market for Other Testing, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)

19 BIOLOGICS SAFETY TESTING MARKET, BY TYPE OF MODALITY

• 19.1. Key Assumptions and Methodology
• 19.2. Biologics Safety Testing Market: Distribution by Type of Modality
  • 19.2.1. Biologics Safety Testing Market for Antibodies, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
  • 19.2.2. Biologics Safety Testing Market for Vaccines, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
  • 19.2.3. Biologics Safety Testing Market for Cell Therapies, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
  • 19.2.4. Biologics Safety Testing Market for Gene Therapies, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
  • 19.2.5. Biologics Safety Testing Market for Biosimilars, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
  • 19.2.6. Biologics Safety Testing Market for Traditional viral-based Therapies, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
  • 19.2.7. Biologics Safety Testing Market for Proteins, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
  • 19.2.8. Biologics Safety Testing Market for Other Modalities, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)

20 BIOLOGICS SAFETY TESTING MARKET, BY TYPE OF TECHNOLOGY

• 20.1. Key Assumptions and Methodology
• 20.2. Biologics Safety Testing Market: Distribution by Type of Technology
  • 20.2.1. Biologics Safety Testing Market for Polymerase Chain Reaction, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
  • 20.2.2. Biologics Safety Testing Market for Traditional Techniques, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
  • 20.2.3. Biologics Safety Testing Market for Chromatographic and Electrophoretic Techniques, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
  • 20.2.4. Biologics Safety Testing Market for Next-Generation Sequencing, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
  • 20.2.5. Biologics Safety Testing Market for Other Technologies, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)

21 BIOLOGICS SAFETY TESTING MARKET, BY END-USER

• 21.1. Key Assumptions and Methodology
• 21.2. Biologics Safety Testing Market: Distribution by End-user
  • 21.2.1. Biologics Safety Testing Market for Pharmaceutical and Biotechnology Companies, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
  • 21.2.2. Biologics Safety Testing Market for Contract Research Organizations / Contract Development and Manufacturing Organizations, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
  • 21.2.3. Biologics Safety Testing Market for Academic and Research Institutes, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)

22 BIOLOGICS SAFETY TESTING MARKET, BY GEOGRAPHICAL REGIONS

• 22.1. Key Assumptions and Methodology
• 22.2. Biologics Safety Testing Market: Distribution by Geographical Regions
  • 22.2.1. Biologics Safety Testing Market in North America, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
    • 22.2.1.1. Biologics Safety Testing Market in the US, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
    • 22.2.1.2. Biologics Safety Testing Market in Canada, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
  • 22.2.2. Biologics Safety Testing Market in Europe, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
    • 22.2.2.1. Biologics Safety Testing Market in Germany, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
    • 22.2.2.2. Biologics Safety Testing Market in the UK, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
    • 22.2.2.3. Biologics Safety Testing Market in France, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
    • 22.2.2.4. Biologics Safety Testing Market in Italy, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
    • 22.2.2.5. Biologics Safety Testing Market in Spain, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
    • 22.2.2.6. Biologics Safety Testing Market in Rest of Europe, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
  • 22.2.3. Biologics Safety Testing Market in Asia-Pacific, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
    • 22.2.3.1. Biologics Safety Testing Market in China, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
    • 22.2.3.2. Biologics Safety Testing Market in Japan, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
    • 22.2.3.3. Biologics Safety Testing Market in India, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
    • 22.2.3.4. Biologics Safety Testing Market in South Korea, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
    • 22.2.3.5. Biologics Safety Testing Market in Rest of Asia-Pacific, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
  • 22.2.4. Biologics Safety Testing Market in Middle East and North Africa, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
    • 22.2.4.1. Biologics Safety Testing Market in Saudi Arabia, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
    • 22.2.4.2. Biologics Safety Testing Market in Egypt, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
    • 22.2.4.3. Biologics Safety Testing Market in Rest of Middle East and North Africa, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
  • 22.2.5. Biologics Safety Testing Market in Latin America, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
    • 22.2.5.1. Biologics Safety Testing Market in Brazil, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
    • 22.2.5.2. Biologics Safety Testing Market in Argentina, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
    • 22.2.5.3. Biologics Safety Testing Market in Rest of Latin America, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)

23 MARKET OPPORTUNITY ANALYSIS: NORTH AMERICA

• 23.1. Biologics Safety Testing Market in North America: Distribution by Type of Offering
  • 23.1.1. Biologics Safety Testing Market in North America for Consumables, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
  • 23.1.2. Biologics Safety Testing Market in North America for Instruments, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
  • 23.1.3. Biologics Safety Testing Market in North America for Services, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
• 23.2. Biologics Safety Testing Market in North America: Distribution by Type of Testing
  • 23.2.1. Biologics Safety Testing Market in North America for Virus Safety Testing, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
  • 23.2.2. Biologics Safety Testing Market in North America for Mycoplasma Testing, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
  • 23.2.3. Biologics Safety Testing Market in North America for Sterility Testing, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
  • 23.2.4. Biologics Safety Testing Market in North America for Endotoxin Testing, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
  • 23.2.5. Biologics Safety Testing Market in North America for Bioburden Testing, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
  • 23.2.6. Biologics Safety Testing Market in North America for Other Testing, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
• 23.3. Biologics Safety Testing Market in North America: Distribution by Type of Modality
  • 23.3.1. Biologics Safety Testing Market in North America for Antibodies, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
  • 23.3.2. Biologics Safety Testing Market in North America for Vaccines, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
  • 23.3.3. Biologics Safety Testing Market in North America for Cell Therapies, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
  • 23.3.4. Biologics Safety Testing Market in North America for Gene Therapies, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
  • 23.3.5. Biologics Safety Testing Market in North America for Biosimilars, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
  • 23.3.6. Biologics Safety Testing Market in North America for Traditional-viral based Therapies, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
  • 23.3.7. Biologics Safety Testing Market in North America for Proteins, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
  • 23.3.8. Biologics Safety Testing Market in North America for Other Modalities, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
• 23.4. Biologics Safety Testing Market in North America: Distribution by Type of Technology
  • 23.4.1. Biologics Safety Testing Market in North America for Polymerase Chain Reaction, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
  • 23.4.2. Biologics Safety Testing Market in North America for Traditional Techniques, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
  • 23.4.3. Biologics Safety Testing Market in North America for Chromatographic and Electrophoretic Techniques, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
  • 23.4.4. Biologics Safety Testing Market in North America for Next-Generation Sequencing, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
  • 23.4.5. Biologics Safety Testing Market in North America for Other Technologies, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
• 23.5. Biologics Safety Testing Market in North America: Distribution by End-user
  • 23.5.1. Biologics Safety Testing Market in North America for Pharmaceutical and Biotechnology Companies, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
  • 23.5.2. Biologics Safety Testing Market in North America for Contract Research Organizations / Contract Development and Manufacturing Organizations, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
  • 23.5.3. Biologics Safety Testing Market in North America for Academic and Research Institutes, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)

24 MARKET OPPORTUNITY ANALYSIS: EUROPE

• 24.1. Biologics Safety Testing Market in Europe: Distribution by Type of Offering
  • 24.1.1. Biologics Safety Testing Market in Europe for Consumables, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
  • 24.1.2. Biologics Safety Testing Market in Europe for Instruments, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
  • 24.1.3. Biologics Safety Testing Market in Europe for Services, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
• 24.2. Biologics Safety Testing Market in Europe: Distribution by Type of Testing
  • 24.2.1. Biologics Safety Testing Market in Europe for Virus Safety Testing, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
  • 24.2.2. Biologics Safety Testing Market in Europe for Mycoplasma Testing, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
  • 24.2.3. Biologics Safety Testing Market in Europe for Sterility Testing, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
  • 24.2.4. Biologics Safety Testing Market in Europe for Endotoxin Testing, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
  • 24.2.5. Biologics Safety Testing Market in Europe for Bioburden Testing, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
  • 24.2.6. Biologics Safety Testing Market in Europe for Other Testing, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
• 24.3. Biologics Safety Testing Market in Europe: Distribution by Type of Modality
  • 24.3.1. Biologics Safety Testing Market in Europe for Antibodies, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
  • 24.3.2. Biologics Safety Testing Market in Europe for Vaccines, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
  • 24.3.3. Biologics Safety Testing Market in Europe for Cell Therapies, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
  • 24.3.4. Biologics Safety Testing Market in Europe for Gene Therapies, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
  • 24.3.5. Biologics Safety Testing Market in Europe for Biosimilars, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
  • 24.3.6. Biologics Safety Testing Market in Europe for Traditional-viral based Therapies, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
  • 24.3.7. Biologics Safety Testing Market in Europe for Proteins, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
  • 24.3.8. Biologics Safety Testing Market in Europe for Other Modalities, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
• 24.4. Biologics Safety Testing Market in Europe: Distribution by Type of Technology
  • 24.4.1. Biologics Safety Testing Market in Europe for Polymerase Chain Reaction, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
  • 24.4.2. Biologics Safety Testing Market in Europe for Traditional Techniques, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
  • 24.4.3. Biologics Safety Testing Market in Europe for Chromatographic and Electrophoretic Techniques, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
  • 24.4.4. Biologics Safety Testing Market in Europe for Next-Generation Sequencing, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
  • 24.4.5. Biologics Safety Testing Market in Europe for Other Technologies, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
• 24.5. Biologics Safety Testing Market in Europe: Distribution by End-user
  • 24.5.1. Biologics Safety Testing Market in Europe for Pharmaceutical and Biotechnology Companies, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
  • 24.5.2. Biologics Safety Testing Market in Europe for Contract Research Organizations / Contract Development and Manufacturing Organizations, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
  • 24.5.3. Biologics Safety Testing Market in Europe for Academic and Research Institutes, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)

25 MARKET OPPORTUNITY ANALYSIS: ASIA-PACIFIC

• 25.1. Biologics Safety Testing Market in Asia-Pacific: Distribution by Type of Offering
  • 25.1.1. Biologics Safety Testing Market in Asia-Pacific for Consumables, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
  • 25.1.2. Biologics Safety Testing Market in Asia-Pacific for Instruments, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
  • 25.1.3. Biologics Safety Testing Market in Asia-Pacific for Services, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
• 25.2. Biologics Safety Testing Market in Asia-Pacific: Distribution by Type of Testing
  • 25.2.1. Biologics Safety Testing Market in Asia-Pacific for Virus Safety Testing, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
  • 25.2.2. Biologics Safety Testing Market in Asia-Pacific for Mycoplasma Testing, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
  • 25.2.3. Biologics Safety Testing Market in Asia-Pacific for Sterility Testing, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
  • 25.2.4. Biologics Safety Testing Market in Asia-Pacific for Endotoxin Testing, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
  • 25.2.5. Biologics Safety Testing Market in Asia-Pacific for Bioburden Testing, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
  • 25.2.6. Biologics Safety Testing Market in Asia-Pacific for Other Testing, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
• 25.3. Biologics Safety Testing Market in Asia-Pacific: Distribution by Type of Modality
  • 25.3.1. Biologics Safety Testing Market in Asia-Pacific for Antibodies, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
  • 25.3.2. Biologics Safety Testing Market in Asia-Pacific for Vaccines, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
  • 25.3.3. Biologics Safety Testing Market in Asia-Pacific for Cell Therapies, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
  • 25.3.4. Biologics Safety Testing Market in Asia-Pacific for Gene Therapies, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
  • 25.3.5. Biologics Safety Testing Market in Asia-Pacific for Biosimilars, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
  • 25.3.6. Biologics Safety Testing Market in Asia-Pacific for Traditional-viral based Therapies, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
  • 25.3.7. Biologics Safety Testing Market in Asia-Pacific for Proteins, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
  • 25.3.8. Biologics Safety Testing Market in Asia-Pacific for Other Modalities, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
• 25.4. Biologics Safety Testing Market in Asia-Pacific: Distribution by Type of Technology
  • 25.4.1. Biologics Safety Testing Market in Asia-Pacific for Polymerase Chain Reaction, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
  • 25.4.2. Biologics Safety Testing Market in Asia-Pacific for Traditional Techniques, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
  • 25.4.3. Biologics Safety Testing Market in Asia-Pacific for Chromatographic and Electrophoretic Techniques, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
  • 25.4.4. Biologics Safety Testing Market in Asia-Pacific for Next-Generation Sequencing, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
  • 25.4.5. Biologics Safety Testing Market in Asia-Pacific for Other Technologies, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
• 25.5. Biologics Safety Testing Market in Asia-Pacific: Distribution by End-user
  • 25.5.1. Biologics Safety Testing Market in Asia-Pacific for Pharmaceutical and Biotechnology Companies, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
  • 25.5.2. Biologics Safety Testing Market in Asia-Pacific for Contract Research Organizations / Contract Development and Manufacturing Organizations, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
  • 25.5.3. Biologics Safety Testing Market in Asia-Pacific for Academic and Research Institutes, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)

26 MARKET OPPORTUNITY ANALYSIS: MIDDLE EAST AND NORTH AFRICA

• 26.1. Biologics Safety Testing Market in Middle East and North Africa: Distribution by Type of Offering
  • 26.1.1. Biologics Safety Testing Market in Middle East and North Africa for Consumables, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
  • 26.1.2. Biologics Safety Testing Market in Middle East and North Africa for Instruments, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
  • 26.1.3. Biologics Safety Testing Market in Middle East and North Africa for Services, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
• 26.2. Biologics Safety Testing Market in Middle East and North Africa: Distribution by Type of Testing
  • 26.2.1. Biologics Safety Testing Market in Middle East and North Africa for Virus Safety Testing, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
  • 26.2.2. Biologics Safety Testing Market in Middle East and North Africa for Mycoplasma Testing, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
  • 26.2.3. Biologics Safety Testing Market in Middle East and North Africa for Sterility Testing, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
  • 26.2.4. Biologics Safety Testing Market in Middle East and North Africa for Endotoxin Testing, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
  • 26.2.5. Biologics Safety Testing Market in Middle East and North Africa for Bioburden Testing, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
  • 26.2.6. Biologics Safety Testing Market in Middle East and North Africa for Other Testing, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
• 26.3. Biologics Safety Testing Market in Middle East and North Africa: Distribution by Type of Modality
  • 26.3.1. Biologics Safety Testing Market in Middle East and North Africa for Antibodies, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
  • 26.3.2. Biologics Safety Testing Market in Middle East and North Africa for Vaccines, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
  • 26.3.3. Biologics Safety Testing Market in Middle East and North Africa for Cell Therapies, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
  • 26.3.4. Biologics Safety Testing Market in Middle East and North Africa for Gene Therapies, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
  • 26.3.5. Biologics Safety Testing Market in Middle East and North Africa for Biosimilars, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
  • 26.3.6. Biologics Safety Testing Market in Middle East and North Africa for Traditional-viral based Therapies, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
  • 26.3.7. Biologics Safety Testing Market in Middle East and North Africa for Proteins, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
  • 26.3.8. Biologics Safety Testing Market in Middle East and North Africa for Other Modalities, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
• 26.4. Biologics Safety Testing Market in Middle East and North Africa: Distribution by Type of Technology
  • 26.4.1. Biologics Safety Testing Market in Middle East and North Africa for Polymerase Chain Reaction, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
  • 26.4.2. Biologics Safety Testing Market in Middle East and North Africa for Traditional Techniques, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
  • 26.4.3. Biologics Safety Testing Market in Middle East and North Africa for Chromatographic and Electrophoretic Techniques, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
  • 26.4.4. Biologics Safety Testing Market in Middle East and North Africa for Next-Generation Sequencing, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
  • 26.4.5. Biologics Safety Testing Market in Middle East and North Africa for Other Technologies, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
• 26.5. Biologics Safety Testing Market in Middle East and North Africa: Distribution by End-user
  • 26.5.1. Biologics Safety Testing Market in Middle East and North Africa for Pharmaceutical and Biotechnology Companies, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
  • 26.5.2. Biologics Safety Testing Market in Middle East and North Africa for Contract Research Organizations / Contract Development and Manufacturing Organizations, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
  • 26.5.3. Biologics Safety Testing Market in Middle East and North Africa for Academic and Research Institutes, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)

27 MARKET OPPORTUNITY ANALYSIS: LATIN AMERICA

• 27.1. Biologics Safety Testing Market in Latin America: Distribution by Type of Offering
  • 27.1.1. Biologics Safety Testing Market in Latin America for Consumables, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
  • 27.1.2. Biologics Safety Testing Market in Latin America for Instruments, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
  • 27.1.3. Biologics Safety Testing Market in Latin America for Services, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
• 27.2. Biologics Safety Testing Market in Latin America: Distribution by Type of Testing
  • 27.2.1. Biologics Safety Testing Market in Latin America for Virus Safety Testing, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
  • 27.2.2. Biologics Safety Testing Market in Latin America for Mycoplasma Testing, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
  • 27.2.3. Biologics Safety Testing Market in Latin America for Sterility Testing, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
  • 27.2.4. Biologics Safety Testing Market in Latin America for Endotoxin Testing, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
  • 27.2.5. Biologics Safety Testing Market in Latin America for Bioburden Testing, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
  • 27.2.6. Biologics Safety Testing Market in Latin America for Other Testing, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
• 27.3. Biologics Safety Testing Market in Latin America: Distribution by Type of Modality
  • 27.3.1. Biologics Safety Testing Market in Latin America for Antibodies, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
  • 27.3.2. Biologics Safety Testing Market in Latin America for Vaccines, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
  • 27.3.3. Biologics Safety Testing Market in Latin America for Cell Therapies, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
  • 27.3.4. Biologics Safety Testing Market in Latin America for Gene Therapies, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
  • 27.3.5. Biologics Safety Testing Market in Latin America for Biosimilars, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
  • 27.3.6. Biologics Safety Testing Market in Latin America for Traditional-viral based Therapies, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
  • 27.3.7. Biologics Safety Testing Market in Latin America for Proteins, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
  • 27.3.8. Biologics Safety Testing Market in Latin America for Other Modalities, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
• 27.4. Biologics Safety Testing Market in Latin America: Distribution by Type of Technology
  • 27.4.1. Biologics Safety Testing Market in Latin America for Polymerase Chain Reaction, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
  • 27.4.2. Biologics Safety Testing Market in Latin America for Traditional Techniques, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
  • 27.4.3. Biologics Safety Testing Market in Latin America for Chromatographic and Electrophoretic Techniques, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
  • 27.4.4. Biologics Safety Testing Market in Latin America for Next-Generation Sequencing, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
  • 27.4.5. Biologics Safety Testing Market in Latin America for Other Technologies, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
• 27.5. Biologics Safety Testing Market in Latin America: Distribution by End-user
  • 27.5.1. Biologics Safety Testing Market in Latin America for Pharmaceutical and Biotechnology Companies, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
  • 27.5.2. Biologics Safety Testing Market in Latin America for Contract Research Organizations / Contract Development and Manufacturing Organizations, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
  • 27.5.3. Biologics Safety Testing Market in Latin America for Academic and Research Institutes, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
• *Detailed information on Chapter 23 to 27 is available in the Excel Data Packs shared along with the report**

28 PORTER'S FIVE FORCES ANALYSIS

• 28.1. Chapter Overview
  • 28.1.1. Significance of Porter's Five Forces Analysis
  • 28.1.2. Porter's Five Forces Analysis
• 28.2. Methodology
• 28.3. Key Parameters
  • 28.3.1. Threats of New Entrants
  • 28.3.2. Bargaining Power of Buyers
  • 28.3.3. Bargaining Power of Solution Providers
  • 28.3.4. Threat of Substitute Solutions
  • 28.3.5. Rivalry Among Existing Competitors
• 28.4. Porter's Five Force Analysis: Harvey Ball Analysis

29 CONCLUDING INSIGHTS

30 EXECUTIVE INSIGHTS

31 APPENDIX I: TABULATED DATA

32 APPENDIX II: LIST OF COMPANIES AND ORGANIZATION

관련자료